Radiodermatitis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Radiodermatitis – Pipeline Review, H1 2017’, provides an overview of the Radiodermatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiodermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Radiodermatitis

The report reviews pipeline therapeutics for Radiodermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Radiodermatitis therapeutics and enlists all their major and minor projects

The report assesses Radiodermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Radiodermatitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Radiodermatitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Radiodermatitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Daiichi Sankyo Company Ltd

FirstString Research Inc

Foresee Pharmaceuticals LLC

Reata Pharmaceuticals Inc

SK Chemicals Co Ltd

viDA Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Radiodermatitis - Overview

Radiodermatitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Radiodermatitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Radiodermatitis - Companies Involved in Therapeutics Development

Daiichi Sankyo Company Ltd

FirstString Research Inc

Foresee Pharmaceuticals LLC

Reata Pharmaceuticals Inc

SK Chemicals Co Ltd

viDA Therapeutics Inc

Radiodermatitis - Drug Profiles

cerium oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granexin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omaveloxolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RS-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKI-2162 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTI-1000 Series - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Radiodermatitis - Dormant Projects

Radiodermatitis - Discontinued Products

Radiodermatitis - Product Development Milestones

Featured News & Press Releases

Jul 25, 2014: Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis

Apr 24, 2014: RTA 408 Lotion Demonstrates Favorable Safety and Pharmacodynamic Response in a Phase 1 Study

Apr 10, 2014: Preclinical Study of Reata's RTA 408 Demonstrates Role in Prevention and Treatment of Radiation Dermatitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Radiodermatitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Radiodermatitis – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Radiodermatitis – Pipeline by FirstString Research Inc, H1 2017

Radiodermatitis – Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Radiodermatitis – Pipeline by Reata Pharmaceuticals Inc, H1 2017

Radiodermatitis – Pipeline by SK Chemicals Co Ltd, H1 2017

Radiodermatitis – Pipeline by viDA Therapeutics Inc, H1 2017

Radiodermatitis – Dormant Projects, H1 2017

Radiodermatitis – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Radiodermatitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports